1093 Overzicht aandelen CSPC Pharmaceutical Group Limited, een investeringsholding, houdt zich bezig met onderzoek en ontwikkeling, productie en verkoop van farmaceutische producten in de Volksrepubliek China, andere Aziatische regio's, Noord-Amerika, Europa en internationaal. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
CSPC Pharmaceutical Group Limited Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor CSPC Pharmaceutical Group Historische aandelenkoersen Huidige aandelenkoers HK$4.81 52 Week Hoogtepunt HK$7.83 52 Week Laag HK$4.45 Bèta 0.64 1 maand verandering -7.68% 3 maanden verandering -3.61% 1 Jaar Verandering -29.99% 3 jaar verandering -41.27% 5 jaar verandering -50.93% Verandering sinds IPO 1,040.15%
Recent nieuws en updates CSPC Pharmaceutical Group Limited Announces SYS6005 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval
Executive Chairman recently bought HK$4.8m worth of stock Dec 18
CSPC Pharmaceutical Group Limited Announces Board Changes Dec 06
Executive Chairman recently bought HK$2.0m worth of stock Nov 20
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 16
Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount? Nov 15 Meer updates bekijken CSPC Pharmaceutical Group Limited Announces SYS6005 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval
Executive Chairman recently bought HK$4.8m worth of stock Dec 18
CSPC Pharmaceutical Group Limited Announces Board Changes Dec 06
Executive Chairman recently bought HK$2.0m worth of stock Nov 20
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 16
Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount? Nov 15
CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024 Nov 06
Investor sentiment deteriorates as stock falls 15% Nov 01
Upcoming dividend of HK$0.16 per share Oct 24
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly Oct 16 CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA
Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26% Sep 30
Investor sentiment improves as stock rises 16% Sep 26
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Sep 21 CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares. Sep 19
Executive Chairman recently bought HK$4.6m worth of stock Sep 10 CSPC Pharmaceutical Group Limited Announces Aprepitant Injection Obtains Drug Registration Approval
Investor sentiment deteriorates as stock falls 17% Aug 28
Executive Chairman recently bought HK$6.7m worth of stock Aug 24
Price target decreased by 9.8% to HK$8.59 Aug 22
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 22
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 November 2024 Aug 21
CSPC Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024 Aug 09
CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected Aug 08
CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jul 11 CSPC Pharmaceutical Group Limited Announces Enlonstobart Injection Obtains Conditional Marketing Approval
CSPC Pharmaceutical Group Limited Obtains Approval from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jun 25
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly Jun 17
CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think May 29 CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 28
Upcoming dividend of HK$0.14 per share May 24
CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14 May 21
CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug (JMT202) Obtains Approval from National Medical Products Administration of the People's Republic of China May 18
CSPC Pharmaceutical Group Limited to Report Q1, 2024 Results on May 27, 2024 May 16
Cspc Pharmaceutical Group Limited Announces That the Peramivir Injection (15Ml:0.15G) (The "Product") Developed by the Group Has Obtained Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China, and Is Deemed to Have Passed the Consistency Evaluation of Quality and Efficacy for Generic Drugs May 15
CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14 Apr 29
CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023 Apr 28
Full year 2023 earnings: EPS and revenues miss analyst expectations Apr 27
CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S Apr 27
There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price Apr 22
Executive Chairman exercised options to buy HK$52m worth of stock. Apr 20
CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14 Apr 01
CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval Mar 23
CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024 Mar 21
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 21
CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate SYS6023 Obtains Clinical Trial Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Mar 21
CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024 Mar 20
CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 09
CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate Jan 22
CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration Jan 15
Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E Jan 04
CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA Dec 18
CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets Dec 12
CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China Dec 02
Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations Dec 01
CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Nov 29
CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Nov 28
CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023 Nov 21
CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China Nov 18
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE Nov 08
CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China Nov 04
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Oct 31
Investor sentiment improves as stock rises 19% Oct 27
CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors Oct 26
CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA Sep 07
Upcoming dividend of HK$0.14 per share at 4.7% yield Aug 31
CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval Aug 30
CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Aug 25
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023 Aug 24
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 24
CSPC Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 23, 2023 Aug 12
Cspc Pharmaceutical Group Limited Announces Biologic License Application of Batoclimab (Hbm9161) Jun 30
CSPC Ouyi Pharmaceutical Co., Ltd. Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Jun 27 CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China
Cspc Pharmaceutical Group Limited Announces That Clinical Trial Application for Cpo301 Jun 09
Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China Jun 07
Elevation Oncology Highlights First-In-Human Phase 1 Sysa1801 (Eo-3021) Clinical Data to Be Presented by Partner Cspc Pharmaceutical Group Limited At Asco 2023 Jun 06
CSPC Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2022 Jun 01
Upcoming dividend of HK$0.11 per share at 3.1% yield May 29
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 27
CSPC Pharmaceutical Group Limited to Report Q1, 2023 Results on May 25, 2023 May 17 Rendement voor aandeelhouders 1093 HK Pharmaceuticals HK Markt 7D 0.2% -3.3% -2.2% 1Y -30.0% -2.4% 18.3%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: 1093 presteerde slechter dan de Hong Kong Pharmaceuticals -sector, die het afgelopen jaar een rendement van -2.4 % opleverde.
Rendement versus markt: 1093 presteerde slechter dan Hong Kong Market , dat het afgelopen jaar een rendement van 18.3 % opleverde.
Prijsvolatiliteit Is 1093's price volatile compared to industry and market? 1093 volatility 1093 Average Weekly Movement 7.4% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.9% 10% most volatile stocks in HK Market 18.7% 10% least volatile stocks in HK Market 4.1%
Stabiele aandelenkoers: 1093 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van 1093 is het afgelopen jaar stabiel geweest.
Over het bedrijf CSPC Pharmaceutical Group Limited, een investeringsholding, houdt zich bezig met onderzoek en ontwikkeling, productie en verkoop van farmaceutische producten in de Volksrepubliek China, andere Aziatische regio's, Noord-Amerika, Europa en internationaal. Het bedrijf is actief in de segmenten Afgewerkte geneesmiddelen, Bulkproducten en Functionele voeding en overige. Het levert NBP zachte capsules en injecties voor acute ischemische beroerte; Oulaining capsules en injecties voor de behandeling van milde tot matige geheugen- en mentale stoornissen; Enxi voor de behandeling van volwassen idiopathische Parkinson; Duomeisu voor lymfoom, multipel myeloom, eierstok- en borstkanker en andere kwaadaardige tumoren; Jinyouli voor de preventie van leucopenie en infectie veroorzaakt door chemotherapie; en Keaili voor borstkanker.
Meer tonen CSPC Pharmaceutical Group Limited Samenvatting Hoe verhouden de winst en inkomsten van CSPC Pharmaceutical Group zich tot de beurswaarde? 1093 fundamentele statistieken Marktkapitalisatie HK$55.98b Inkomsten(TTM ) HK$5.49b Inkomsten(TTM ) HK$32.23b
10.2x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) 1093 resultatenrekening (TTM ) Inkomsten CN¥30.27b Kosten van inkomsten CN¥8.90b Brutowinst CN¥21.37b Overige uitgaven CN¥16.21b Inkomsten CN¥5.16b
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) 0.44 Brutomarge 70.59% Nettowinstmarge 17.04% Schuld/Eigen Vermogen Verhouding 1.1%
Hoe presteerde 1093 op de lange termijn?
Bekijk historische prestaties en vergelijking Dividenden
6.6% Huidig dividendrendement
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2024/12/20 22:51 Aandelenkoers aan het einde van de dag 2024/12/20 00:00 Inkomsten 2024/09/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten CSPC Pharmaceutical Group Limited wordt gevolgd door 50 analisten. 27 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Wai Chak Yuen BOCI Research Ltd. Sharon Shi BOCI Research Ltd. Ethan Cui BofA Global Research
Toon 47 meer analisten 
